Get access

Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart

Authors

  • F. Cremonini,

    1. Division of Gastroenterology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Search for more papers by this author
  • G. Chiarioni,

    1. Division of Gastroenterology of the University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy and Division of Gastroenterology and Hepatology, Center for Functional GI & Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Search for more papers by this author
  • A. Lembo

    1. Division of Gastroenterology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Search for more papers by this author

Address for Correspondence
F. Cremonini, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rabb Rose 1, Boston, MA 02215, USA.
Tel: +617 667 1093; fax: +617 667 2767;
e-mail: fcremoni@bidmc.harvard.edu

Abstract

Chronic constipation (CC) is widely prevalent in the Western world, with a significant negative impact on quality of life, yet new and effective pharmacological and non-pharmacological treatment options have only recently emerged. The article by Tack and colleagues in the current issue of NGM is timely with the recent introduction of the serotonin type 4 receptor agonist prucalopride in Europe and wider acceptance of anorectal biofeedback for patients with pelvic floor dyssynergia. This Editorial (i) highlights the importance of identifying patients with pelvic floor dysfunction who are candidates for pelvic floor retraining programs and (ii) discusses the potential limitations of the 5-HT4 agonist, prucalopride, as an early option in the treatment algorithm for CC.

Ancillary